References in periodicals archive ?
The data on the use of hENT1 as a biomarker in the metastatic setting have been less robust.
There is less evidence to support the predictive value of hCNT3 expression in estimating response to adjuvant gemcitabine compared to hENT1. Marechal et al.
Clovis Oncology noted that the study also demonstrated that hENT1 status had no impact on survival for patients on gemcitabine.
Separately 30 patients were evaluated for hENT1 expression level at time of initial AML diagnosis before standard cytarabine containing treatment.
The main aim of the ongoing 50-patient trial is to evaluate response rates to elacytarabine combination treatment after cytarabine combination treatment has failed and the relationship of outcome to the patient's hENT1 status.
hENT1 (Human Equilibrative Nucleoside Transporter 1) is a protein that is present on the surface of cancer cells and has been proven to play an important role in the uptake and efficacy of gemcitabine.
23 April 2010 - Norwegian cancer drug developer Clavis Pharma ASA (OSL: CLAVIS) said yesterday its partner for the CP-4126 drug candidate, Clovis Oncology Inc has signed a contract to develop and commercialise the hENT1 companion diagnostic with US firm Ventana Medical Systems.
M2 PHARMA-May 31, 2011-Clavis Pharma gets NOK14m grant to develop hENT1 biomarker assay for AML patients(C)2011 M2 COMMUNICATIONS
In 2011, it expects to see results from the elacytarabine Phase II trial in early-stage AML, and from two studies for CP-4126 being carried out in close collaboration with US biopharmaceutical company Clovis Oncology; a Phase II trial in second-line pancreatic cancer patients and a retrospective observational study of hENT1 expression in pancreatic cancer patients.
The entry of gemcitabine into tumour cells is dependent upon the expression of specific membrane transporter proteins, particularly hENT1. Gemcitabine is the current standard treatment for advanced pancreatic cancer, and is also used in combination with other chemotherapy agents for the treatment of other cancers, including ovarian, non-small cell lung and breast cancer.
30 April 2010 - Norwegian cancer drug development company Clavis Pharma ASA (OSL: CLAVIS) said today that it has inked a licence agreement with Ventana Medical Systems Inc, a wholly owned member of the Roche Group (VTX: ROG), providing Ventana with exclusive access to Clavis Pharma's monoclonal antibody targeting human nucleoside transporter 1 (hENT1) and to the hybridoma cell line that produces the antibody.
23 April 2010 - Norwegian cancer drug developer Clavis Pharma said yesterday its partner for the CP-4126 drug candidate, Clovis Oncology Inc, has signed a contract to develop and commercialise the hENT1 companion diagnostic with US firm Ventana Medical Systems.
Acronyms browser ?
Full browser ?
- Hensen, Victor
- Henshaws Society for Blind People
- Hensing ligament
- Hensing, Friedrich W
- Hensing, Friedrich W.
- Hensley, Elam & Associates
- Henslow, John Stevens
- Henslowe, Philip
- Henson Digital Performance Studio
- Henson James Maury
- Henson Matthew Alexander
- Henson Valley Montessori School
- Henson, Burdge and Evans
- Henson, Jim
- Henson, Jim
- Henson, Jim
- Henson, Josiah
- Henson, Matthew
- Henson, Matthew Alexander
- Hentai Computer Graphics
- Hentai Heaven
- Hentai Kamen
- Hentai Ninja Clan
- Hentai Social Club
- Hentai Weeaboo Master Lords
- Hentai X-Press
- Henty Machinery Field Days
- Henty, George Alfred
- Henyey track
- Henyey track stars
- Henze, Hans Werner